[{"address1": "400, boulevard Gonthier d\u2019Andernach", "address2": "Parc d\u2019innovation CS80166 Cedex", "city": "Illkirch-Graffenstaden", "zip": "67405", "country": "France", "phone": "33 3 88 27 91 00", "fax": "33 3 88 27 91 11", "website": "https://www.transgene.fr", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.", "fullTimeEmployees": 141, "companyOfficers": [{"maxAge": 1, "name": "Dr. Alessandro  Riva M.D.", "age": 62, "title": "CEO & Chairman of the Board", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 570032, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christophe  Ancel PharmD", "age": 58, "title": "Director of Pharmaceutical Operations, Chief Pharmacist & Deputy CEO", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 198952, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lucie  Larguier", "title": "Chief Financial Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric  Quemeneur Ph.D., Pharm.D.", "age": 58, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Felitti J.D., LLM", "age": 53, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christelle  Schwoerer", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Maud  Brandely-Talbot M.D., Ph.D.", "age": 69, "title": "VP of Medical Affairs & Chief Medical Officer", "yearBorn": 1954, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. James  Wentworth M.B.A., Ph.D.", "title": "VP & Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gaelle  Stadtler", "age": 39, "title": "VP & Director of Human Resources", "yearBorn": 1984, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kaidre  Bendjama", "title": "Project Leader of Personalized Cancer Vaccines", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.62, "open": 1.62, "dayLow": 1.62, "dayHigh": 1.62, "regularMarketPreviousClose": 1.62, "regularMarketOpen": 1.62, "regularMarketDayLow": 1.62, "regularMarketDayHigh": 1.62, "beta": 0.731, "forwardPE": -1.9390244, "volume": 100, "regularMarketVolume": 100, "averageVolume": 11, "marketCap": 210347472, "fiftyTwoWeekLow": 1.3, "fiftyTwoWeekHigh": 1.85, "priceToSalesTrailing12Months": 26.626263, "fiftyDayAverage": 1.59, "twoHundredDayAverage": 1.5915, "currency": "USD", "enterpriseValue": 161501728, "profitMargins": -2.82633, "floatShares": 26445361, "sharesOutstanding": 132294000, "heldPercentInsiders": 0.7353, "heldPercentInstitutions": 0.012159999, "bookValue": 0.155, "priceToBook": 10.258064, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -22328000, "trailingEps": -0.24, "forwardEps": -0.82, "enterpriseToRevenue": 20.443, "enterpriseToEbitda": -5.679, "exchange": "OEM", "quoteType": "EQUITY", "symbol": "TRGNF", "underlyingSymbol": "TRGNF", "shortName": "TRANSGENE", "longName": "Transgene SA", "firstTradeDateEpochUtc": 1610116200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a4e3e150-53a6-3f5a-b524-63cdcca1982f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.59, "recommendationKey": "none", "totalCash": 15666000, "totalCashPerShare": 0.156, "ebitda": -28440000, "totalDebt": 17295000, "quickRatio": 1.693, "currentRatio": 1.791, "totalRevenue": 7900000, "debtToEquity": 110.78, "revenuePerShare": 0.079, "returnOnAssets": -0.336, "returnOnEquity": -0.83542997, "freeCashflow": 2833500, "operatingCashflow": -34671000, "revenueGrowth": -0.263, "grossMargins": -2.74532, "operatingMargins": -4.67931, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]